Introduction {#S0001}
============

Severe asthma is a collection of phenotypes and endotypes with several pathophysiological characteristics that result in poor control and frequent exacerbations. Approximately in 50% of patients with severe refractory asthma, there is strong evidence of the pathogenic role of T helper type-2 (Th2) cytokines, such as IL-5, IL-4 and IL-13, which lead to the eosinophilic and allergic inflammatory processes.[@CIT0001] These patients, who are on maintenance treatment with oral corticosteroids (OCS), represent up to 46% of severe asthma population.[@CIT0002] The impact of OCS and their side effects are also very relevant, in terms of quality of life and pharmacoeconomic impact.[@CIT0003] Luckily, the increasing knowledge on inflammatory phenotypes has driven the development of targeted biological therapies, especially selective targeted monoclonal antibodies (mAbs).

Among the recently developed anti-asthma biologic drugs, the fully human mAb dupilumab is an interesting therapeutic option, given its ability to inhibit the biological effects of both IL-4 and IL-13. This drug is directed against the shared IL-4 receptor alpha subunit: binding to the receptor, it blocks the signaling pathway of both IL-4 and IL-13, with very promising data in terms of asthma control and reduction in the use of OCS.[@CIT0004] The advent of mAbs, starting from omalizumab, has not generated particular concerns about their safety and their long usage, thanks to the accumulation of data on these matters.[@CIT0005] On the contrary, the new therapeutic options, including dupilumab, lack of evidence on safety, especially in the long term. Phase III studies have shown that dupilumab, as add-on maintenance therapy, has a significant effect on improving lung function and reducing the rate of asthmatic exacerbations, regardless of baseline blood eosinophil count.[@CIT0006] Treatment with dupilumab is particularly useful in patients with severe asthma and associated comorbidities (atopic dermatitis, chronic sinusitis and nasal polyposis), who remain inadequately controlled with usual asthma therapies.[@CIT0006] In patients with elevated eosinophil levels and persistent moderate-to-severe asthma, dupilumab therapy was associated with fewer asthma exacerbations when long-acting beta-adrenoceptor agonist (LABA) and inhaled glucocorticoids were withdrawn.[@CIT0007] In patients with severe steroid-dependent asthma, dupilumab demonstrated a steroid-sparing action with a simultaneous reduction of severe exacerbations rate and increase of FEV~1~.[@CIT0004] The recent VENTURE randomized clinical trial (RCT) showed a significant, but transient, blood eosinophilia in the dupilumab group with respect to placebo group (14% vs 1%)[@CIT0004]

In this article, we describe the case of a patient with severe refractory asthma treated with dupilumab, who developed early high blood eosinophils levels and finally a chronic eosinophilic pneumonia (CEP). At our best knowledge, this event is the first reported in literature.

Case presentation {#S0002}
=================

A 56-year-old man, nonsmoker, came to our observation. He was a retired cleaning maintenance technician. Remote clinical history included chronic sinusitis with nasal polyposis, treated with functional endoscopic sinus surgery, a hospitalization in Cardiology Unit in 2011 for a vasospastic angina episode, caused by myocardial bridging without significant stenosis of the remaining coronary tracts. In 2010, a diagnosis of allergic asthma was made. Skin prick tests were positive for house-dust mites, birch and grass and negative for aspergillus fumigatus. Serum precipitins against Aspergillus antigens were negative. Pulmonary function tests showed a severe obstruction (FEV~1~ 1.95 L, 54% of predicted; FEV~1~/FVC 57%) with a complete bronchial reversibility after 400 μg of inhaled salbutamol (FEV~1~ 54%; +16%). Antineutrophil cytoplasmic antibodies were negative without signs and symptoms compatible with vasculitis. The patient did not have a history of sensitivity to NSAIDs. On February 2016, a chest high-resolution CT scan showed no pleural and parenchymal abnormalities. Total IgE were 406.9 IU/mL, blood eosinophils 660 cells/mm^3^ and fractional exhaled nitric oxide (FeNO) value (ppb) 43. Asthma Control Questionnaire-5 (ACQ) score was 3.40, which confirmed poor control of asthma. The pharmacological therapy included formoterol/beclomethasone metered-dose inhaler 100/6 μg, two daily inhalations and as needed (twice a day on an average), tiotropium bromide 2.5 μg soft mist inhaler, montelukast 10 mg/day. Montelukast was then suspended because ineffectiveness. Due to frequent exacerbations (on average 5 every 12 months), the patient took at least 4 OCS bursts annually. Given the linger of poor asthma control, with continuous worsening leading to 3 exacerbations in three consecutive months, the patient was enrolled in a phase III RCT on dupilumab in July 2016,[@CIT0004] with subcutaneous administration of the drug at a dose of 300 mg every 2 weeks. At the third administration of dupilumab, a blood eosinophil value of 1840 cells/mm^3^ was detected with an improvement in spirometric data (FEV~1~ 66%, +22% compared to pre-treatment data). FeNO value was 13 ppb. During dupilumab treatment and after the clinical improvement, the patient no longer needed OCS therapy. ACQ-5 score was 0.20, indicative of the marked improvement in asthmatic symptoms. The increase in blood eosinophilia was not alarming because in line with what reported in other patients, and also in light of the clinical and spirometric improvement, we decided to continue with dupilumab treatment. In RCTs was found a much higher percentage of patients with blood eosinophilia in the dupilumab group compared to the placebo group (14% vs 1%).[@CIT0004]

On December 7, 2016, the patient arrived at the Center to perform the 10th injection of dupilumab. The patient reported fever up to 38.5°C from about 7 days. Chest X ray showed pulmonary bilateral opacities ([Figure 1](#F0001){ref-type="fig"}), for which the patient was treated with azithromycin 500 mg per day for 6 days.Figure 1Chest x-ray: bilateral pulmonary opacities.

Due to the persistence of the symptoms, a chest high-resolution CT scan was performed, which showed bilateral consolidations with air bronchogram, localized in the upper lobes and the superior lower lobe on the right ([Figure 2](#F0002){ref-type="fig"}).Figure 2Chest high-resolution CT scan pre-post oral corticosteroids (OCS) treatment: (**A**) bilaterally, areas of parenchymal thickening with plane bronchograms, confluent, located in the upper lobes bilaterally, and peripherally, in the postero-lateral mantle area of the supero-lateral segment of the upper lobe. (**B**) Areas of parenchymal thickening with plane bronchograms on the apical of the inferior right lobe. (**C, D**) Resolution of parenchymal thickening after OCS therapy.

Blood tests showed a further increase in blood eosinophilia (2080 cells/mm^3^). For these reasons, it was decided to discontinue dupilumab treatment and the patient was admitted at the Department of Pneumology on December 12, 2016. Upon presentation, his blood pressure was 120/80 mmHg, with a heart rate of 84 bpm. He was breathing at a rate of 18 bpm and his oxygen saturation was 97%. Complete blood count revealed a white cell count of 10,360 cells/mm^3^ with eosinophilic rate of 26.2%. Reactive C protein value was 16.2 mg/dL. Arterial blood gases revealed pH 7.42; pO~2~ 71.4 mmHg; pCO~2~ 35 mmHg; HCO~3~ 25.1 mmol/L.

We therefore started an empiric antibiotic treatment (piperacillin/tazobactam 4.5 g IV every 6 hrs for 10 days and levofloxacin 750 mg once a day for 8 days) without any changes in symptoms. The patient underwent a fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB/TBB). BAL revealed eosinophils alveolitis (60%), whereas TBB showed large fragments of pulmonary parenchyma with inflammatory infiltrate rich in eosinophilic granulocytes, associated with focal aspects of organizing pneumonia and pneumocytes hyperplasia ([Figure 3](#F0003){ref-type="fig"}). There were no extravascular granulomas, small and medium-sized vessels vasculitis. The finding was therefore compatible with CEP. A hematological examination was also performed and a search for FIP1L1-PDGFRA, a fusion gene that determines the excessive growth of eosinophils, was recommended. This molecular analysis was negative.Figure 3Biopsies: (**A**) transbronchial biopsies sampled several good-quality lung fragments (hematoxylin-eosin, 20× magnification). (**B**) A subacute lung injury was present, consisting of foci of organizing pneumonia with pneumocyte hyperplasia and several interstitial and intra-alveolar eosinophils (hematoxylin-eosin, 400× magnification). (**C**) In some areas, intra-alveolar foamy macrophages were intermingled with eosinophils (hematoxylin-eosin, 400× magnification). There were no extravascular granulomas, small and medium-sized vessels vasculitis.

In consideration of the obtained results, we started therapy with prednisolone 50 mg per day for 30 days. Subsequently, a gradual OCS tapering was initiated, and also a rapid clinical improvement and disappearance of fever was noted. The OCS was then suspended after a total of 6 months of therapy and after a new chest CT scan performed in July 2017, confirming resolution of parenchymal thickening. At the end of the OCS therapy, the value of blood eosinophils was 40 cells/mm^3^.

Discussion {#S0003}
==========

The term "eosinophilic lung disease" (ELD) summarizes a group of lung diseases caused by an increase of eosinophils within the lung parenchyma. ELD can be diagnosed in the presence of thoracic opacifications associated with blood eosinophilia, parenchymal eosinophilia confirmed by pulmonary biopsy and important eosinophilia confirmed by BAL. They are divided into diseases with known cause (parasitic infection, allergic bronchopulmonary aspergillosis or drug toxicity), with unknown cause (Loeffler syndrome, acute (AEP) and CEP or idiopathic hypereosinophilic syndrome), and eosinophilic vasculitis (eosinophilic granulomatosis with polyangiitis previously known as Churg--Strauss syndrome).[@CIT0008]

Among ELD, eosinophilic pneumonia (EP) is an uncommon entity with respiratory symptoms such as dyspnoea and cough, lasting more than 2 weeks. Up to 50% of patients with EP have a history of asthma. AEP and CEP are usually associated with alveolar eosinophilia 40% or greater on BAL and usually blood hyper-eosinophilia.[@CIT0009] Radiologically EP is characterized by unilateral or bilateral opacities generally with no segmental distribution, often localized in the upper lobes without basilar involvement.[@CIT0010] Diagnosis often requires BAL and/or TBB to confirm respiratory eosinophilia and to exclude other entities, such as infection or malignancy.

In addition to anti-IL-5 Mabs, dupilumab also showed efficacy in patients with severe refractory eosinophilic asthma, regardless of the level of basal blood eosinophilia.[@CIT0004],[@CIT0007],[@CIT0011] In our patient, we found high blood eosinophilia, radiological bilateral consolidation with aerial bronchogram localized in the upper lobes and lower lobe of the right lung. Significant eosinophilia in BAL was also detected, and histological specimens obtained by TBB confirmed the diagnosis of CEP. It is not possible to define with certainty the causes of CEP. As described above, the patient was affected by severe refractory eosinophilic and allergic asthma, and for this reason, he had undergone therapy with dupilumab. Since the beginning of this treatment, simultaneously to a great improvement in asthma control, there was a progressive increase in blood eosinophils count and subsequent onset of clinical-radiological pattern suggestive of ELD/CEP ([Figure 4](#F0004){ref-type="fig"}). Although we are not able to establish a certain cause--effect relationship between dupilumab and CEP, it is known that airway eosinophilopoietic processes are modulated by type 2 cytokines such as IL-4 and IL-13, which have been shown to trigger the migratory responses of the hematopoietic stem and progenitor cells (HSPCs) to the airways in asthmatic subjects.[@CIT0012] In these processes, other cytokines such as IL-33 are involved. This could promote systemic and local eosinophilic inflammation also by inducing IL-5 production.[@CIT0013] From recent data, it seems that HSPCs have an even more complex role through interaction with the alarmins TSLP, IL-33 and IL-25.[@CIT0012] In fact, HSPCs express the thymic stromal lymphopoietin receptor and the IL-33 receptor (IL1RL1/ST2). Stimulation of HSPCs with TSLP results in a dose-dependent release of several cytokines, such as IL-5, IL-13, GM-CSF, C-C chemokine (CCL) 22, thymus and activation regulation chemokine, IL-8 and CCL1.[@CIT0014] The priming effects of TSLP and IL-33 are inhibited in the presence of the respective receptor blocking antibodies, in particular the IL-13Ra1 antibody.[@CIT0014] Alarmins induce the synthesis of IL-4 and IL-13 from HPC, well-known priming agents of the HSPCs themselves. It has therefore been hypothesized that alarmins directly stimulate the migration of HSPCs with an IL-13-dependent mechanism, which can therefore be modified by pharmacological interactions, such as the ones with dupilumab.[@CIT0015]Figure 4Case report timeline.

Eosinophils represent the largest IL-4-competent population in steady-state allergic tissues and in type 2 inflammatory contexts.[@CIT0016]--[@CIT0018] It is also known that the production of IL-4 by eosinophils is extremely important in the regulation of multiple metabolic pathways.[@CIT0019] Consequently, in addition to stimulating IL-5 production, the role of IL-4 and IL-13 in the "T2-high" inflammatory pathway should be considered central. Notionally, Webb et al., highlighted the interaction between these three cytokines and observed that the levels of IL-5 and blood eosinophilia produced in the absence of IL-4 are significantly greater in IL13--/-- mice than in wild-type mice. In addition, it seemed that low levels of IL-13 may result in the activation of NF-kB and an IL-4-independent mechanism of IL-5 production and eosinophil mobilization, suggesting alternative mechanisms of eosinophils activation which should be further studied.[@CIT0020],[@CIT0021]

Based on previously published data,[@CIT0022] the dupilumab-induced IL-4 and IL-13 receptor blockade may have resulted in an alteration of the complex immune-allergic pathway in our patient. This pathway is affected by both allergic and eosinophilic asthmatic endotypes, and consequently, the concomitant action of allergenic stimuli and eosinophils, mediated by a large number of important cytokines including not only Il-4 and IL-13, but also alarmins and IL-5, could have caused the appearance of eosinophilic pneumonia during treatment with dupilumab. Another possibility is the correlation with antibiotic therapy. However, eosinophils levels were high before the antibiotic treatment beginning, the pulmonary thickening was already present, and there were no signs of purulent sputum or cough and therefore it seems unlikely to be induced by the azithromycin. As a last hypothesis, it is also possible, though less likely, that the withdrawal of OCS, as a consequence of the steroid-sparing effect of dupilumab, has evidenced the presence of CEP, which was not secondary to the action of the dupilumab itself.

Conclusion {#S0004}
==========

To our knowledge, this is the first reported case of CEP as a possible severe side effect of dupilumab administration. Nowadays, dupilumab seems to be generally well tolerated, but large-scale studies are required to establish its long-term safety and tolerability. We suggest a close monitoring of blood eosinophils count and clinical parameters in patients with severe refractory asthma treated with this mAb, which remains a very promising and effective therapeutic option.
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